Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
Teinturier R, Abou Ziki R, Kassem L, Luo Y, Malbeteau L, Gherardi S, Corbo L, Bertolino P, Bachelot T, Treilleux I, Zhang CX, Le Romancer M. Teinturier R, et al. Among authors: bachelot t. Breast Cancer Res Treat. 2021 Dec;190(3):389-401. doi: 10.1007/s10549-021-06339-9. Epub 2021 Sep 24. Breast Cancer Res Treat. 2021. PMID: 34561764 Free PMC article.
Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes.
Thomachot MC, Bendriss-Vermare N, Massacrier C, Biota C, Treilleux I, Goddard S, Caux C, Bachelot T, Blay JY, Menetrier-Caux C. Thomachot MC, et al. Among authors: bachelot t. Int J Cancer. 2004 Jul 10;110(5):710-20. doi: 10.1002/ijc.20146. Int J Cancer. 2004. PMID: 15146561
Dendritic cell infiltration and prognosis of early stage breast cancer.
Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C, Lebecque S. Treilleux I, et al. Among authors: bachelot t. Clin Cancer Res. 2004 Nov 15;10(22):7466-74. doi: 10.1158/1078-0432.CCR-04-0684. Clin Cancer Res. 2004. PMID: 15569976
[Neoadjuvant chemotherapy and ovarian cancer].
Ray-Coquard I, Saba C, Bachelot T, Méeus P, Mignotte H, Blondet R, Treilleux I, Peix M, Guastalla JP. Ray-Coquard I, et al. Among authors: bachelot t. Bull Cancer. 2006 Jul;93(7):669-76. Bull Cancer. 2006. PMID: 16873075 Free article. Review. French.
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Falandry C, Debled M, Bachelot T, Delozier T, Crétin J, Romestaing P, Mille D, You B, Mauriac L, Pujade-Lauraine E, Freyer G. Falandry C, et al. Among authors: bachelot t. Breast Cancer Res Treat. 2009 Aug;116(3):501-8. doi: 10.1007/s10549-008-0229-5. Epub 2008 Nov 20. Breast Cancer Res Treat. 2009. PMID: 19020973 Clinical Trial.
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.
Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Ray-Coquard I, Puisieux A, Caux C, Blay JY, Ménétrier-Caux C. Gobert M, et al. Among authors: bachelot t. Cancer Res. 2009 Mar 1;69(5):2000-9. doi: 10.1158/0008-5472.CAN-08-2360. Epub 2009 Feb 24. Cancer Res. 2009. PMID: 19244125
332 results